Diagnostic yield of massively parallel sequencing in patients with chronic kidney disease of unknown etiology: rationale and design of a national prospective cohort study. Issue 4 (7th April 2022)

• Record Type: Journal Article
• Authors: de Haan, Amber; Eijgelsheim, Mark; Vogt, Liffert; van der Zwaag, Bert; van Eerde, Albertien M; Knoers, Nine V A M; de Borst, Martin H
• Is Part Of: BMJ open. Volume 12:Issue 4(2022)
• Publication Date: 2022-04-07
• Subjects: NEPHROLOGY -- End stage renal failure -- Chronic renal failure -- GENETICS; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2021-057829
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Chronic kidney disease (CKD) can be caused by a variety of systemic or primary renal diseases. The cause of CKD remains unexplained in approximately 20% of patients. Retrospective studies indicate that massively parallel sequencing (MPS)-based gene panel testing may lead to a genetic diagnosis in 12%–56% of patients with unexplained CKD, depending on patient profile. The diagnostic yield of MPS-based testing in a routine healthcare setting is unclear. Therefore, the primary aim of the VARIETY (Validation of algoRithms and IdEnTification of genes in Young patients with unexplained CKD) study is to prospectively address the diagnostic yield of MPS-based gene panel testing in patients with unexplained CKD and an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 before the age of 50 years in clinical practice. Methods and analysis: The VARIETY study is an ongoing, prospective, nationwide observational cohort study to investigate the diagnostic yield of MPS-based testing in patients with unexplained CKD in a routine healthcare setting in the Netherlands. Patients are recruited from outpatient clinics in hospitals across the Netherlands. At least 282 patients will be included to meet the primary aim. Secondary analyses include subgroup analyses according to age and eGFR at first presentation, family history, and the presence of extrarenal symptoms. Ethics and dissemination: Ethical approval for the study has been obtained from the institutional review board of the University Medical Center Groningen. Study findings should inform physicians and policymakers towards optimal implementation of MPS-based diagnostic testing in patients with unexplained CKD.